Inflammation as a Predictor of Abdominal Aortic Aneurysm Growth and Rupture: A Systematic Review of Imaging Biomarkers

European Journal of Vascular and Endovascular Surgery

Volumn 52, Issue 3, 2016, Pages 333-342

  Jalalzadeh, H ^a   Indrakusuma, R ^a   Planken, R N ^a   Legemate, D A ^a   Koelemay, M J W ^a   Balm, R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Abdominal; Aneurysm; Aortic aneurysm; Biomarkers; Diagnostic imaging; Growth; Inflammation; Ruptured

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; DEXTRAN; FERUMOXTRAN-10; MAGNETITE NANOPARTICLE; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL AORTA ANEURYSM; COCHRANE LIBRARY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG UPTAKE; EMBASE; HUMAN; IMAGE ANALYSIS; INFLAMMATION; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ABDOMINAL AORTA; ABDOMINAL AORTIC ANEURYSM; AORTIC RUPTURE; AORTITIS; AORTOGRAPHY; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE COURSE; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR;

AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; AORTITIS; AORTOGRAPHY; COMPUTED TOMOGRAPHY ANGIOGRAPHY; CONTRAST MEDIA; DEXTRANS; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETITE NANOPARTICLES; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84973547658     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2016.05.002     Document Type: Review

References (31)

1. 1 Thompson, R.W., Geraghty, P.J., Lee, J.K., Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg 39:2 (2002), 110–230.
2. 2 Reeps, C., Essler, M., Pelisek, J., Seidl, S., Eckstein, H.H., Krause, B.J., Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg 48:2 (2008), 417–423 discussion 24.
3. 3 Sadat, U., Taviani, V., Patterson, A.J., Young, V.E., Graves, M.J., Teng, Z., et al. Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of abdominal aortic aneurysms–a feasibility study. Eur J Vasc Endovasc Surg 41:2 (2011), 167–174.
4. 4 Tawakol, A., Migrino, R.Q., Bashian, G.G., Bedri, S., Vermylen, D., Cury, R.C., et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48:9 (2006), 1818–1824.
5. 5 Rudd, J.H., Warburton, E.A., Fryer, T.D., Jones, H.A., Clark, J.C., Antoun, N., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105:23 (2002), 2708–2711.
6. 6 Tahara, N., Imaizumi, T., Virmani, R., Narula, J., Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis. J Nucl Med 50:3 (2009), 331–334.
7. 7 Turner, G.H., Olzinski, A.R., Bernard, R.E., Aravindhan, K., Boyle, R.J., Newman, M.J., et al. Assessment of macrophage infiltration in a murine model of abdominal aortic aneurysm. Journal of Magnetic Resonance Imaging: JMRI 30:2 (2009), 455–460.
8. 8 Kooi, M.E., Cappendijk, V.C., Cleutjens, K.B., Kessels, A.G., Kitslaar, P.J., Borgers, M., et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107:19 (2003), 2453–2458.
9. 9 Golestani, R., Sadeghi, M.M., Emergence of molecular imaging of aortic aneurysm: implications for risk stratification and management. J Nucl Cardiol 21:2 (2014), 251–267 quiz 268–70.
10. 10 Richards, J.M., Semple, S.I., MacGillivray, T.J., Gray, C., Langrish, J.P., Williams, M., et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging 4:3 (2011), 274–281.
11. 11 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(7), 2009, e1000097.
12. 12 Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4, 2015, 1.
13. 13 Chien, P.F., Khan, K.S., Siassakos, D., Registration of systematic reviews: PROSPERO. BJOG 119:8 (2012), 903–905.
14. 14 (WHO) WHO. International Clinical Trials Registry Platform (ICTRP). http://wwwwhoint/ictrp/en/ [accessed 20.11.15].
15. 15 Whiting, P.F., Rutjes, A.W., Westwood, M.E., Mallett, S., Deeks, J.J., Reitsma, J.B., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:8 (2011), 529–536.
16. 16 Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. (Clinical research ed) BMJ, 343, 2011, d5928.
17. 17 Kotze, C.W., Groves, A.M., Menezes, L.J., Harvey, R., Endozo, R., Kayani, I.A., et al. What is the relationship between 18F-FDG aortic aneurysm uptake on PET/CT and future growth rate?. Eur J Nucl Med Mol Imaging 38:8 (2011), 1493–1499.
18. 18 Kotze, C.W., Rudd, J.H.F., Ganeshan, B., Menezes, L.J., Brookes, J., Agu, O., et al. CT signal heterogeneity of abdominal aortic aneurysm as a possible predictive biomarker for expansion. Atherosclerosis 233:2 (2014), 510–517.
19. 19 Morel, O., Mandry, D., Micard, E., Kauffmann, C., Lamiral, Z., Verger, A., et al. Evidence of cyclic changes in the metabolism of abdominal aortic aneurysms during growth phases: 18F-FDG PET Sequential Observational Study. J Nucl Med 56:7 (2015), 1030–1035.
20. 20 Nchimi, A., Cheramy-Bien, J.P., Gasser, T.C., Namur, G., Gomez, P., Seidel, L., et al. Multifactorial relationship between 18F-fluoro-deoxy-glucose positron emission tomography signaling and biomechanical properties in unruptured aortic aneurysms. Circ Cardiovasc Imaging 7:1 (2014), 82–91.
21. 21 Kotze, C.W., Menezes, L.J., Endozo, R., Groves, A.M., Ell, P.J., Yusuf, S.W., Increased metabolic activity in abdominal aortic aneurysm detected by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg 38:1 (2009), 93–99.
22. 22 Sakalihasan, N., Van Damme, H., Gomez, P., Rigo, P., Lapiere, C.M., Nusgens, B., et al. Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 23:5 (2002), 431–436.
23. 23 McBride, O.M., Berry, C., Burns, P., Chalmers, R.T., Doyle, B., Forsythe, R., et al. MRI using ultrasmall superparamagnetic particles of iron oxide in patients under surveillance for abdominal aortic aneurysms to predict rupture or surgical repair: MRI for abdominal aortic aneurysms to predict rupture or surgery-the MA(3)RS study. Open Heart, 2(1), 2015, e000190.
24. 24 Kokje, V.B., Hamming, J.F., Lindeman, J.H., Editor's Choice – pharmaceutical management of small abdominal aortic aneurysms: a systematic review of the clinical evidence. Eur J Vasc Endovasc Surg 50:6 (2015), 702–713.
25. 25 Satomi, T., Ogawa, M., Mori, I., Ishino, S., Kubo, K., Magata, Y., et al. Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide. J Nucl Med 54:6 (2013), 999–1004.
26. 26 Millon, A., Dickson, S.D., Klink, A., Izquierdo-Garcia, D., Bini, J., Lancelot, E., et al. Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner. Atherosclerosis 228:2 (2013), 339–345.
27. 27 Song, F., Khan, K.S., Dinnes, J., Sutton, A.J., Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 31:1 (2002), 88–95.
28. 28 United States Food and Drug Administration (FDA). 2015. URL: http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm, [accessed 20.11.15].
29. 29 Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, Ferumoxytol versus other intravenous iron therapies for anemia: a review of the clinical and cost-effectiveness and guidelines – an update. 2014 Nov 21.
30. 30 Bashir, M.R., Bhatti, L., Marin, D., Nelson, R.C., Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 41:4 (2015), 884–898.
31. 31 Hope, M.D., Hope, T.A., Zhu, C., Faraji, F., Haraldsson, H., Ordovas, K.G., et al. Vascular imaging with ferumoxytol as a contrast agent. AJR Am J Roentgenol 205:3 (2015), W366–W373.